Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could weak muscles mean higher bleeding risk for seniors on blood thinners?

NCT ID NCT07173075

Knowledge-focused Sponsor: University Hospital, Clermont-Ferrand Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study looks at whether older adults (70+) with low muscle mass are more likely to have serious bleeding while taking common blood thinners (apixaban or rivaroxaban). Researchers will compare muscle mass in 110 patients who had a bleeding event with those who did not. The goal is to see if simple muscle measurements can help predict bleeding risk.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this could help doctors identify elderly patients at higher risk of bleeding while on blood thinners, potentially leading to safer prescribing.
What could go wrong
This is an observational study with only 110 participants, so it cannot prove cause and effect. Results may not apply to all older adults or other blood thinners.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 110 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Oct 2025

An estimate. Start dates often move.

Expected to finish

Oct 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

70 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * age of at least 70 years * treated with one of the two factor Xa inhibitors used in France: Apixaban, Rivaroxaban. * For cases : hemorrhagic event causing hospitalization * For controls : free from hemorrhagic events. Exclusion Criteria: * Failure to obtain a consent form * Patient under legal protection (guardianship, curatorship, or legal safeguard) * Recurrent bleeding from a pre-existing lesion that has not received specific treatment. For example: unexplored gastrointestinal bleeding, cutaneous bleeding from a cancerous wound with therapeutic abstention. * Bleeding caused by high-velocity trauma, surgery, or assault * Contraindications to impedance measurement: pacemaker, cardiac defibrillator * Elements that may provide erroneous impedance measurement data: bilateral limb amputation, bilateral joint replacements, dialysis. * Unable to maintain the supine position. * Digestive absorption disorder (celiac disease, short bowel, stoma, etc.)

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Denutrition are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Hemorrhage nutritional deficiency disease Sarcopenia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Denutrition Direct oral anticoagulant Elderly Hemmorhage Muscle mass Sarcopenia

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • CHU de Clermont-Ferrand

    Clermont-Ferrand, 63000, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.